Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services

Custom Projects and Consultation from Experimental Panel Design to Data Analysis

            Providing Instrument Access Prior to Purchase Decision and Much‑Needed Capacity for Customers Affected by COVID-19 Related Laboratory Closures

            New Collaboration via Therapeutic Insights Services Provides Visikol Customers Access to Rich Data and Powerful Analysis Tools from Imaging Mass Cytometry

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced its new Therapeutic Insights Services business, designed to provide researchers with sample-to-answer mass cytometry and Imaging Mass Cytometry (IMC) services for a broad range of research needs.

The menu of Therapeutic Insights offerings includes consultation from experimental panel design to data analysis, custom antibody sourcing, conjugation and verification, staining for IMC with standard or custom panels, mass cytometry or IMC data acquisition and powerful data analysis tools.

“By broadening the access to mass cytometry and IMC, Therapeutic Insights Services provides researchers with new capabilities in interrogating the tissue microenvironment, helping them answer important questions in developmental biology, disease progression and response to therapy,” said Chris Linthwaite, Fluidigm President and CEO. “There are more than 1,000 important publications based on mass cytometry, documenting meaningful findings across immunology, immune function, immuno-oncology and infectious disease, including immune profiling in the fight against the unprecedented COVID-19 pandemic.

“Customers affected by COVID-19 related closures of local research facilities, as well as those who wish to use mass cytometry and IMC before making an instrument purchase decision, will now have access to this important technology,” said Linthwaite. “In addition, Fluidigm will provide opportunities for Therapeutic Insights Services customers to provide feedback on new panels and analysis tools prior to their release.

“We are excited for the opportunity to share this platform and its considerable capabilities with many more researchers in the global scientific community.”

Concurrently with the launch of Therapeutic Insights Services, Fluidigm and Visikol, a leader in advanced tissue imaging and digital pathology services, announced a collaboration that will enable Visikol to offer its customers access to Fluidigm IMC technology. Visikol is a contract research organization focused on advanced drug discovery emphasizing bio-imaging, bioinformatics and image analysis.